Chen Mingzhe, Guo Shanqi, Wang Junxin, Wang Nan, Wen Simeng, Zhang Hongtuan, Wang Yong, Liu Ranlu, Xu Yong, Jiang Xingkang
Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Department of Urology, Tianjin Medical University General Hospital, Tianjin, China.
Transl Androl Urol. 2025 Mar 30;14(3):507-518. doi: 10.21037/tau-24-533. Epub 2025 Mar 26.
Elevated prostate-specific antigen (PSA) levels often lead to prostate biopsies, which can result in overdiagnosis and complications, thereby increasing preoperative anxiety. This study aimed to develop and validate a novel biopsy-free diagnostic nomogram for accurate detection of clinically significant prostate cancer (csPCa) in patients with PSA levels ≥20 ng/mL.
The cohort of this retrospective analysis included patients with PSA levels ≥20 ng/mL who underwent evaluation including clinical variables, Prostate Imaging-Reporting and Data System (PI-RADS), prostate health index (PHI), and prostate-specific membrane antigen positron emission tomography-computed tomography (PSMA PET/CT). Nomogram performance was evaluated using the concordance index, calibration plot, decision curve analysis, and the area under the receiver operating characteristic curve (AUC).
Of 684 patients, 478 and 206 were randomly assigned to the diagnostic and validation cohorts, respectively. Multivariable predictors of csPCa included age, PSA density, PI-RADS, location of suspicious lesion, %PSA variation ratio, and acute urinary retention. The foundational nomogram achieved AUCs of 0.930 and 0.911 for the training and validation sets, respectively. By integrating both PHI and PSMA maximum standardized uptake value (SUVmax), the diagnostic accuracy of the advanced nomogram improved significantly, with AUCs of 0.951 and 0.935 for the training and validation sets, respectively. Limitations included the lack of external validation and potential selection bias.
The biopsy-free nomogram presents a promising approach for accurate diagnosis of csPCa in patients with PSA levels ≥20 ng/mL. This non-invasive method can reduce unnecessary biopsies and enhance patient care by identifying those necessitating further evaluation and treatment.
前列腺特异性抗原(PSA)水平升高常导致前列腺活检,这可能导致过度诊断和并发症,从而增加术前焦虑。本研究旨在开发并验证一种新型的无需活检的诊断列线图,用于准确检测PSA水平≥20 ng/mL患者的临床显著性前列腺癌(csPCa)。
这项回顾性分析的队列包括PSA水平≥20 ng/mL且接受了包括临床变量、前列腺影像报告和数据系统(PI-RADS)、前列腺健康指数(PHI)以及前列腺特异性膜抗原正电子发射断层扫描-计算机断层扫描(PSMA PET/CT)等评估的患者。使用一致性指数、校准图、决策曲线分析以及受试者工作特征曲线下面积(AUC)来评估列线图的性能。
在684例患者中,分别有478例和206例被随机分配到诊断队列和验证队列。csPCa的多变量预测因素包括年龄、PSA密度、PI-RADS、可疑病变位置、PSA变化率百分比以及急性尿潴留。基础列线图在训练集和验证集上的AUC分别为0.930和0.911。通过整合PHI和PSMA最大标准化摄取值(SUVmax),高级列线图的诊断准确性显著提高,训练集和验证集的AUC分别为0.951和0.935。局限性包括缺乏外部验证和潜在的选择偏倚。
无需活检的列线图为准确诊断PSA水平≥20 ng/mL患者的csPCa提供了一种有前景的方法。这种非侵入性方法可以减少不必要的活检,并通过识别那些需要进一步评估和治疗的患者来改善患者护理。